Anne Donovan, MD
Family Medicine · Walton, KYNPI 1124061981
Payments from drug & device makers
Across 93 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$369
- Axsome Therapeutics, Inc.$243
- Pfizer$202
- Abbott$148
- Novo Nordisk$140
- AstraZeneca$138
- plus $988 from 23 others
What the payments were for
- Food & beverage$2,229100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $369 |
| Axsome Therapeutics, Inc. | 3 | $243 |
| Pfizer | 13 | $202 |
| Abbott | 9 | $148 |
| Novo Nordisk | 8 | $140 |
| AstraZeneca | 2 | $138 |
| Idorsia Pharmaceuticals US Inc | 2 | $132 |
| Amgen | 5 | $109 |
| Corcept Therapeutics | 1 | $100 |
| Lilly USA, LLC | 6 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $79 |
| Johnson & Johnson | 3 | $65 |
| GSK | 4 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,229 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $123,969 |
| JardianceEmpagliflozin | 42 | $64,270 |
| MounjaroTirzepatide | 33 | $61,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $51,324 |
| TrulicityDulaglutide | 30 | $46,359 |
| RybelsusSemaglutide | 17 | $45,613 |
| FarxigaDapagliflozin Propanediol | 23 | $30,787 |
| JanuviaSitagliptin Phosphate | 16 | $25,390 |
| Victoza 3-PakLiraglutide | 26 | $23,459 |
| Bydureon BciseExenatide Microspheres | 19 | $21,292 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $18,840 |
| XareltoRivaroxaban | 13 | $17,555 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $9,891 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,270 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $8,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $140 | $169,58186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $88 | $107,70363 claims |
| Boehringer IngelheimJardiance | $13 | $64,27042 claims |
| GSKTrelegy Ellipta | $64 | $51,32460 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $138 | $45,17150 claims |
| MerckJanuvia | $20 | $25,39016 claims |
| Johnson & JohnsonXarelto | $65 | $17,55513 claims |
| PfizerPaxlovid | $202 | $1,36521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Walton
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.